Get the Stockscreener App
700.42
0.53%
-2.8447
Regeneron Pharmaceuticals Inc stock is traded at $700.42, with a volume of 184.27K.
It is down -0.53% in the last 24 hours and up +6.39% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$703.26
Open:
$705.11
24h Volume:
184.27K
Relative Volume:
0.17
Market Cap:
$73.54B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
16.77
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
-5.72%
1M Performance:
+6.39%
6M Performance:
+35.15%
1Y Performance:
-11.23%
1-Day Range:
$698.30
$711.15
1-Week Range:
$698.30
$744.23
52-Week Range:
$476.49
$791.49
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
699.75 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.97 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
420.99 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.66 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
195.65 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MSN
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now - TradingView
Ossiam Sells 22,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Stock Slides 11% With A 8-Day Losing Spree - Trefis
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention (NASDAQ:REGN) - Seeking Alpha
Regeneron’s (REGN) recovery and Dupixent strength support BMO’s outperform rating - MSN
Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating - Insider Monkey
Why Is Kymera Therapeutics Stock Skyrocketing Monday?Kymera Therapeutics (NASDAQ:KYMR) - Benzinga
Natixis Purchases 2,751 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting - GlobeNewswire Inc.
Anti-VEGF Market Growth Outlook: USD 41.3 Billion by 2035 With - openPR.com
California Public Employees Retirement System Sells 158,734 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
14 Best US Stocks to Buy for Long Term - Insider Monkey
Regeneron (REGN) Showcases Promising Trial Data for Lynozyfic in Multiple Myeloma - GuruFocus
Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic™ for Newly Diagnosed Multiple Myeloma - Quiver Quantitative
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment - The Manila Times
Federated Hermes Inc. Acquires 204,045 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Understanding Momentum Shifts in (REGN) - news.stocktradersdaily.com
Can Regeneron Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Does Regeneron’s Choppy 2025 Share Price Reflect Its Long Term Growth Potential? - Yahoo Finance
Regeneron's experimental therapy combo effective in untreated cancer patients - Reuters
Marshall Wace LLP Has $125.95 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
First Trust Advisors LP Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Baird Financial Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Amundi - MarketBeat
Canaccord Genuity Group Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock - MarketBeat
Is Regeneron Still Attractive After Recent Pipeline Milestones and Valuation Upside Signals? - simplywall.st
BMO Capital Markets Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Retail & Free Safe Entry Trade Signal Reports - Newser
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Guggenheim Capital LLC - MarketBeat
Invesco Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsOptions Play & Community Driven Trade Alerts - Newser
Dodge & Cox Acquires 1,502,198 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Holdings Lowered by Epoch Investment Partners Inc. - MarketBeat
Will Regeneron Pharmaceuticals Inc. (RGO) stock profit from fiscal stimulus2025 Retail Activity & Daily Momentum Trading Reports - Newser
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Can Regeneron Pharmaceuticals Inc. (RGO) stock sustain institutional flowsJuly 2025 Update & High Accuracy Trade Alerts - Newser
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - Insider Monkey
Citi Healthcare In Brief: Launch Trajectories Under Scrutiny - Citeline News & Insights
Can Regeneron Pharmaceuticals Inc. stock sustain institutional interestMarket Volume Report & Weekly Top Stock Performers List - Newser
Market Whales and Their Recent Bets on REGN Options - Benzinga
REGN: BMO Capital Raises Price Target and Maintains Outperform R - GuruFocus
BMO Capital raises Regeneron Pharma stock price target to $850 on Dupixent growth - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to "Equal Weight" at Morgan Stanley - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Lido Advisors LLC - MarketBeat
How Does Regeneron Pharmaceuticals Stock Stack Up Against Its Peers? - Trefis
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Schroder Investment Management Group - MarketBeat
Canaccord Genuity Adjusts PT on Regeneron Pharmaceuticals to $1,057 From $850, Maintains Buy Rating - marketscreener.com
Regeneron Pharmaceuticals, Inc. $REGN Position Cut by Groupe la Francaise - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock sustain high P E ratiosMarket Growth Summary & Long-Term Safe Investment Ideas - Newser
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):